Thanks to this research, CDK4/6 inhibitors may be a good therapy option for AM patients with concurrent two aberrations of CDK4 gain, p16INK4A loss or CCND1 gain. This evidence concerns the gene CCND1 and acute myeloblastic leukemia with maturation.